Robot maker · registered
Sinovation Medical (HKHS)
Neurosurgical robotics maker (SR series / Sinobot X1, Q300 miniature robot) for stereotactic procedures such as SEEG electrode placement and brain biopsy; robot-assisted biopsy showed 98% diagnostic rate with significantly shorter operating time versus frame-based methods. NMPA-approved via China's innovative-device channel and FDA 510(k)-cleared for the US market (2023, with a further clearance in 2025).
Company overview
Identity and operating footprint
Robot models
Specifications remain vendor-claimed
Sinobot X1 (SR1-3D)
- FDA 510(k) clearance K220072 granted June 18, 2023
US regulatory market clearance
Claim source
Deployment log
Announced and cited only
Funding history
Publicly announced rounds
Series D+
Cinda Kunpeng, Shuimu Investment, Junshan Capital, Huiyu Investment, Denuo Capital
Round sourceSeries D
US-China Green Fund (Yangtze Delta), Denuo Capital, Rongquan Capital, Kaifeng Ventures
Round sourceCompany timeline
Milestones and announcements
Source ledger
4 unique public sources